KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Share-based Compensation (2016 - 2026)

Esperion Therapeutics filings provide 8 years of Share-based Compensation readings, the most recent being $2.4 million for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 14.9% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.9 million, a 17.7% decrease, with the full-year FY2025 number at $9.9 million, down 17.7% from a year prior.
  • Share-based Compensation hit $2.4 million in Q4 2025 for Esperion Therapeutics, up from $2.3 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $8.6 million in Q2 2021 to a low of $2.3 million in Q3 2025.
  • Median Share-based Compensation over the past 5 years was $3.1 million (2023), compared with a mean of $3.7 million.
  • Biggest five-year swings in Share-based Compensation: surged 376.89% in 2021 and later tumbled 58.91% in 2022.
  • Esperion Therapeutics' Share-based Compensation stood at $4.5 million in 2021, then fell by 16.96% to $3.7 million in 2022, then decreased by 21.4% to $2.9 million in 2023, then dropped by 3.94% to $2.8 million in 2024, then fell by 14.9% to $2.4 million in 2025.
  • The last three reported values for Share-based Compensation were $2.4 million (Q4 2025), $2.3 million (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.